bicalutamid kabi 150 mg potahované tablety por tbl flm 98x150mg - Резултати от търсенето

Белгия - английски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bicalutamide sandoz 150 mg film-coat. tabl.

sandoz sa-nv - bicalutamide 150 mg - film-coated tablet - 150 mg - bicalutamide 150 mg - bicalutamide

Белгия - английски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bicalutamide teva 50 mg film-coat. tabl.

teva pharma belgium sa-nv - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide

САЩ - английски - NLM (National Library of Medicine)

bicalutamide tablet

remedyrepack inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see us